Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ZD1839 (IRESSA) Clear all
Completed Phase 1 Interventional

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00310154
View directory record Official record
Conditions
Lung Cancer
Interventions
docetaxel, gefitinib, laboratory biomarker analysis, radiation therapy
Drug · Other · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 2 Interventional Results available

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

NCT00229723
View directory record Official record
Conditions
Neoplasms, Squamous Cell
Interventions
Gefitinib (Iressa), cisplatin, radiotherapy
Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Aurora, Colorado • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2009 · Synced Nov 13, 2026, 10:14 AM EST
Terminated Phase 3 Interventional Results available

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

NCT00088907
View directory record Official record
Conditions
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
Interventions
docetaxel, placebo, gefitinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 2 Interventional

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

NCT00193284
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Gefitinib, Docetaxel, Carboplatin, Fluorouracil
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Nov 13, 2026, 10:14 AM EST
Not listed Phase 3 Interventional

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00006048
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, gefitinib, gemcitabine hydrochloride
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Nov 13, 2026, 10:14 AM EST
Terminated Phase 2 Interventional Results available

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

NCT00493025
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, gefitinib, paclitaxel, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 1Phase 2 Interventional

Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

NCT00026299
View directory record Official record
Conditions
Colorectal Cancer
Interventions
ZD1839, oxaliplatin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
12
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Nov 13, 2026, 10:14 AM EST
Not listed Phase 3 Interventional

ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00006049
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gefitinib, paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00411047
View directory record Official record
Conditions
Lung Cancer
Interventions
gefitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Nov 13, 2026, 10:14 AM EST
Terminated Phase 1Phase 2 Interventional

Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer

NCT00093652
View directory record Official record
Conditions
Esophageal Cancer
Interventions
gefitinib, oxaliplatin, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Nov 13, 2026, 10:14 AM EST
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Nov 13, 2026, 10:14 AM EST
Terminated Phase 2 Interventional Results available

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00467077
View directory record Official record
Conditions
Kidney Cancer
Interventions
PEG-interferon alfa-2b, gefitinib
Biological · Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 2 Interventional

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

NCT00062062
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gefitinib, paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
140
States / cities
Scottsdale, Arizona • Fort Collins, Colorado • Jacksonville, Florida + 88 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 1 Interventional

Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

NCT00027625
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
gefitinib, temozolomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 2 Interventional Results available

Iressa Study in Patients With Salivary Gland Cancer

NCT00509002
View directory record Official record
Conditions
Salivary Gland Cancer
Interventions
Gefitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 3 Interventional Results available

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

NCT00656136
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
placebo, BIBW 2992
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
14
States / cities
Kingman, Arizona • Fayetteville, Arkansas • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 2 Interventional

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

NCT00229697
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Gefitinib, Tamoxifen
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
4
States / cities
Berkeley, California • Palm Springs, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 2 Interventional

ZD 1839 in Treating Patients With Metastatic Kidney Cancer

NCT00012337
View directory record Official record
Conditions
Kidney Cancer
Interventions
gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

NCT00100945
View directory record Official record
Conditions
Esophageal Cancer
Interventions
gefitinib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
119
States / cities
Mobile, Alabama • Jacksonville, Florida • Aurora, Illinois + 77 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 2 Interventional

ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

NCT00014183
View directory record Official record
Conditions
Kidney Cancer
Interventions
gefitinib
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 1 Interventional

Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors

NCT00084786
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel, gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 3 Interventional

Iressa Expanded Access Program (EAP)

NCT00034879
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung, Metastases, Neoplasm
Interventions
ZD1839 (Gefitinib)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
626
States / cities
Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 623 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Nov 13, 2026, 10:14 AM EST
Completed Phase 2 Interventional Results available

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

NCT00126555
View directory record Official record
Conditions
Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Interventions
Gefitinib, Radiotherapy, Conventional surgery, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Nov 13, 2026, 10:14 AM EST
Terminated Phase 2 Interventional

Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast

NCT00082667
View directory record Official record
Conditions
Breast Cancer
Interventions
gefitinib, Surgery
Drug · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
35 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Nov 13, 2026, 10:14 AM EST